Introduction
============

Health care practitioners and researchers have been fighting human immunodeficiency virus (HIV) infection for over two decades. During this time, significant progress has been made in understanding the pathogenesis, clinical presentation, and epidemiology of the disease. The advent of antiretroviral therapy has significantly improved the prognosis and quality of life of persons living with HIV. Currently, over 20 antiretroviral drugs have been approved by the Food and Drug Administration (FDA) for the treatment of HIV infection. These agents are classified into: (a) nucleoside/nucleotide reverse transcriptase inhibitors (NRTI/NtRTI), (b) non-nucleoside reverse transcriptase inhibitors (NNRTI), (c) protease inhibitors (PI), and (d) fusion inhibitors. Despite the increased number of choices, issues of adherence, tolerability, long-term toxicity, and drug resistance remain to be some of the major challenges in the management of HIV. To address these problems, advances have been made in the development of novel agents and fixed-dose combination treatment regimens with greater potency, lower toxicity, and improved convenience for patients.

Central among the factors affecting adherence and compliance in the treatment of HIV/AIDS are antiretroviral dosing frequency and pill burden. The effort toward reduced dosing frequency and pill burden has led to the first FDA-approved, once a day, single pill treatment for HIV that contains three antiretroviral medications -- efa-virenz, tenofovir, and emtricitabine. However, many patients must continue to take more complicated and toxic HIV therapeutic regimens due to drug intolerance or drug resistance ([@b33]; [@b48]). Tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) is a once-daily, fixed-dose NtRTI/NRTI combination that has demonstrated efficacy in well-designed clinical trials with good follow up ([@b42]; [@b13]; [@b43]). TDF-FTC combines the benefits of less toxicity, dosing simplicity, and favorable pharmacokinetic properties ([Table 1](#tbl1){ref-type="table"}). This article will review the current use of this versatile NtRTI/NRTI combination in the management of HIV patients.

###### 

Pharmacokinetic characteristics of once-a-day NRTI agents

  Agent                                 Meal/food effect                                                      Oral bio-availability                     Serum half-life   Intracellular half-life   Elimination and metabolism
  ------------------------------------- --------------------------------------------------------------------- ----------------------------------------- ----------------- ------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Emtricitabine (FTC)                   No regard to meal                                                     93%                                       10 h              \>20 h                    Renal excretion; dosage adjustment in renal insufficiency
  Lamivudine (3TC)                      No regard to meal                                                     86%                                       5--7 h            18--22 h                  Renal excretion; dosage adjustment in renal insufficiency
  Abacavir/Lamivudine (ABC/3TC)         No regard to meal (Alcohol increases ABC to 41%, no regard to meal)   83%/86%                                   1.5 h/5--7 h      12--26 h/18--22 h         Metabolized by alcohol dehydrogenase and glucuronyl transferase; renal excretion of metabolites 82%; not for patients with CrCl \<50 mL/min
  Emtricitabine/Tenofovir (FTC/TDF)     No regard to meal                                                     93%/25% fasting, 39% with high fat meal   10 h/17 h         \>20 h/\>60 h             Renal excretion; dosage adjustment in renal insufficiency; not for patients with CrCl \<30 mL/min
  Didanosine (ddl)                      Level decreases 55%; take ½ h before or 2 h after meal                30%--40%                                  1.5 h             \>20 h                    Renal excretion 50%; dosage adjustment in renal insufficiency
  Tenofovir disoproxil fumarate (TDF)   no regard to meal                                                     25% fasting, 39% with high-fat meal       17 h              \>60 h                    Renal excretion 50%; dosage adjustment in renal insufficiency; not for patients with CrCl \<30 mL/min
  Abacavir/Lamivudine ABC               No regard to meal (Alcohol increases ABC to 41%, no regard to meal)   83%                                       1.5 h             12--26 h                  Metabolized by alcohol dehydrogenase and glucuronyl transferase; renal excretion of metabolites 82%

Adopted from DHHS guidelines, Table 11, May 4, 2006.

(US Department of Health and Human Services, Panel on Clinical Practice for Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Version May 4, 2006. Available at: [http://www.aidsinfo.nih.gov/contentfiles/adultand adolescentgl.pdf](http://www.aidsinfo.nih.gov/contentfiles/adultand adolescentgl.pdf).Accessed May 16, 2006)

To better understand the characteristics of TDF-FTC, it is essential to examine its components, TDF and FTC ([Table 2](#tbl2){ref-type="table"}).

###### 

Characteristics of tenofovir and emtricitabine

  Characteristics                              TDF                             FTC                                  TDF-FTC[a](#tf2-1){ref-type="table-fn"}
  -------------------------------------------- ------------------------------- ------------------------------------ -------------------------------------------------
  Generic/Brand name                           Tenofovir DF/Viread             Emtricitabine/Emtriva                Truvada
  Manufacturer                                 Gilead Sciences                 Gilead Sciences                      Gilead Sciences
  FDA approval date                            October 2001                    July 2003                            August 2004[a](#tf2-1){ref-type="table-fn"}
  Supplied as                                  300 mg tabs                     200 mg caps                          300 mg TDF + 200 mg FTC in one tab
  Recommended dose                             300 mg daily                    200 mg daily                         1 tab daily
  Administration                               Orally with or without food     Orally with or without food          Orally with or without food
  Median fasted oral bioavailability (range)   25 (not calculated -- 45)       93 (83.1--106.4)                     25 for TDF 92 for FTC
  Food effect                                  None                            None                                 None
  Toxicity                                     Minimal                         Minimal                              Minimal
                                               GI intolerance Nephrotoxicity   Hyperpigmentation of palm and sole   GI intolerance Hyperpigmentation Nephrotoxicity

Obtained accelerated approval in the US.

Tenofovir disoproxil fumarate (TDF, Viread^®^)
==============================================

Approved by the FDA in 2001, TDF (the ester prodrug of tenofovir) is hydrolyzed to tenofovir intracellularly and phosphorylated to the active metabolite, tenofovir diphosphate ([@b30]). Tenofovir is a nucleotide analog of deoxyadenosine monophosphate, with activity against HIV-1, -2 and Hepatitis B virus (HBV) ([@b36]; [@b47]). Because of its long half-life (17 hours), it is administered once daily with other antiretroviral drugs. Several clinical trials indicated that TDF is highly potent in both treatment-naïve and experienced patients at reducing HIV viral load significantly ([@b55]; [@b14]; [@b39]). It was also shown to be effective as an alternative antiviral agent during treatment failure or drug toxicity among treatment-experienced patients ([@b30]). It can be taken without regard to food consumption, but is absorbed 39% when taken with a fatty meal compared to 25% when administered before a meal (fasting) ([@b58]).

TDF is excreted unchanged by the kidneys; thus, renal tubular toxicity is an important but uncommon side effect ([@b46]; [@b1]; [@b23]; [@b38]; [@b52]). Caution and dose adjustment is recommended in renal insufficiency/failure ([@b58]). TDF is not metabolized by cytochrome P450 enzymes, so little potential for interactions with drugs metabolized by these enzymes exists. TDF induces little or no mitochondrial toxicity or dyslipidemia. Other occasional adverse reactions include nausea, diarrhea, vomiting, rash, and flatulence.

Emtricitabine (FTC, Emtriva^®^)
===============================

Emtricitabine, FTC is a fluorinated derivative of lamivudine (3TC), an analog of deoxycitidine, which is active against HIV-1, -2 and hepatitis B virus. It has been approved by the FDA for use since 2003 and is currently recommended as part of an initial preferred HIV treatment regimen ([@b51]). As compared to 3TC, FTC has a longer half-life, higher oral bioavailability, and slightly greater potency *in vitro*, although the clinical significance of this remains unclear ([@b51]; [@b12]). Studies indicate that FTC is efficacious in combination with other antiretrovirals in reducing HIV viral loads in both treatment-naïve and experienced patients ([@b34]; [@b6]; [@b49]; [@b35]). FTC can be taken without regard to food consumption and is completely eliminated via the kidneys, so dosage adjustment is required in case of renal insufficiency ([@b50]). Potential drug interactions and toxicity, including mitochondrial toxicities and dyslipidemias, are nearly absent. The most common side effects include headache, insomnia, diarrhea, nausea, vomiting, and rash ([@b6]; [@b49]). FTC may cause skin hyperpigmentation of the palms and soles in African and African American patients.

Tenofovir-emtricitabine (Truvada^®^)
====================================

TDF-FTC is a once daily treatment composed of TDF and FTC to be used in combination with other antiretroviral drugs. The TDF-FTC co-formulation contains 300 mg of TDF and 200 mg of FTC administered orally in one tablet that has bioavailability equivalence to the single drug formulations. TDF and FTC have synergistic antiviral effects on HIV-1 and HIV-2 ([@b29]; [@b17]). The co-formulation is considered efficacious therapy that can be used in multi-drug HIV treatment regimens ([@b13]; [@b43]). Recently, the US Department of Health and Human Services listed TDF and FTC among the preferred options as part of NNRTI or PI based antiviral combination therapy ([@b51]; [@b19]). TDF-FTC with the NNRTI efavirenz represents the most simplified antiretroviral dosing schedule yet, consisting of two pills or a single three-drug, fixed-dose combination tablet (Atripla^®^) once a day. When combined with one of three currently recommended ritonavir-boosted PIs, the daily pill burden is a total of 4 or 5 pills. The only other preferred NRTI fixed-dose combination pill, zidovudine (ZDV) +3TC (Combivir^®^), is given twice a day. Other once-a-day NRTI combinations include fixed-dose abacavir + lamivudine (Epzicom^®^) and didanosine with either TDF or stavudine (D4T) extended release. Abacavir + lamivudine, while efficacious and well tolerated, has somewhat less clinical trial data supporting its use and at this time remains an alternate recommendation in guidelines. Didanosine combined with either TDF or D4T extended has a higher incidence of toxicity and is not recommended as first-line therapy ([@b51]; [@b19]).

TDF-FTC efficacy
================

Gilead study 934 was the pivotal efficacy trial for the TDF-FTC combination ([@b43]). This randomized, open-label, noninferiority trial enrolled 517 antiretroviral-naïve, HIV-infected patients to receive either TDF + FTC and efavirenz or ZDV + 3TC and efavirenz. The primary endpoint was the proportion of patients with an HIV RNA level \<400 copies/mL in patients without baseline non-nucleoside resistance. Through week 96, significantly more patients receiving TDF + FTC achieved and maintained an HIV RNA level \<400 copies/mL (75% vs 62%). The TDF + FTC group also demonstrated a significantly greater increase in CD4+ lymphocyte counts (270 vs 237 cells/mm^3^; p = 0.036).

Another clinical trial, Gilead 903, a randomized, placebo-controlled study, compared TDF or D4T in combination with 3TC and efavirenz in 602 treatment-naïve subjects. This study demonstrated equivalence in the percentage of subjects with HIV RNA \<50 copies/mL at week 48 and through 144 with less lipoatrophy and more favorable lipid profiles in the TDF arm ([@b14]). In treatment-experienced patients, the TDF-FTC is commonly used as guided by drug resistance testing, but the relative benefit of the combination relative to other NRTI/NtRTI choices is difficult to gauge and will depend on many factors, including HIV genotypic or phenotypic susceptibility scores, drug interactions, and compliance. It is well documented that 3TC benefits patients with the RT M184V/I mutation that are incompletely suppressed virologically, possibly as a result of impairing viral fitness or residual virologic activity, and likely this holds true of FTC as well.

Therapeutic use of TDF-FTC among special populations
====================================================

No efficacy differences have been identified between male and female patients ([@b17]). Sufficient data is not available to examine differences among different races and ethnic groups and geriatric populations. Because both TDF and FTC are excreted via the kidneys, modification of TDF-FTC dosage and special caution is necessary when treating patients with renal impairments ([Table 3](#tbl3){ref-type="table"}) ([@b17]; [@b3]). Data on dosing in patients with liver impairment is limited; however, no dosing adjustment is recommended ([@b17]).

###### 

TDF, FTC and TDF-FTC dosing in renal insufficiency and hepatic failure

  Drug                Standard dose     Dose for renal insufficiency/failure                                            Dose in hemodialysis   Hepatic failure
  ------------------- ----------------- ------------------------------------------------------------------------------- ---------------------- -------------------
  TDF                 300 mg qd         CrCl 30--49: 300 mg q 48 h 10--29: 300 mg 2×/wk\<10: No recommendation          300 mg/wk              Standard dose
  FTC                 200 mg qd         CrCl 30--49: 200 mg q 48 h 15--29: 200 mg q 72 h \<15: 200 mg q 96 h            200 mg q96 h           No recommendation
  Truvada (TDF/FTC)   300 mg/200 mgqd   CrCl \>50 standard dose qd 30--49: every 48 h \<30 should not be administered   Not administered       Standard dose

([@b3]; [@b17])

TDF and FTC are both active against HBV in vitro, in case series ([@b5]), and in a small controlled clinical trial with HIV-HBV coinfected subjects ([@b41]), but are not approved for that indication. While FTC has no activity against lamivudine-resistant HBV strains, in HIV co-infected patients with a positive HBeAg, the inclusion of TDF in the HIV regimen resulted in a significant reduction of viral load, including those with lamivudine-resistant strains ([@b40]; [@b11]). TDF also may be active against strains of HBV resistant to the NtRTI adefovir and be more potent as well ([@b45]; [@b26]). In its most recent guideline, the American Association for the Study of Liver Disease (AASLD) has also included TDF and FTC as one of the drugs that may be used to treat HIV-HBV co-infected patients ([@b4]; [@b28]). While the efficacy and safety of TDF-FTC has not been thoroughly studied in the treatment of HIV-HBV co-infection, several studies have indicated that discontinuation of TDF-FTC in HBV-infected patients may result in severe and acute exacerbation or flare up of the hepatitis ([@b7]; [@b3]). Liver function tests should be monitored for at least several months in HIV/HBV co-infected patients who are suspended from treatment with TDF-FTC. Because of the risk of HIV resistance with two-drug therapy, if co-infected patients require treatment, other agents such as adefovir or pegylated interferon should be used.

TDF-FTC is excreted in breast milk and should not be used while nursing ([@b17]). The effects of TDF-FTC in pregnant and nursing mothers need to be investigated further in light of its future use.

Resistance and cross-resistance
===============================

Resistance to TDF is conferred by the reverse transcriptase (RT) K65R and/or K70E mutations ([@b59]). K65R can be selected by TDF as well as the NRTIs abacavir and didanosine. This mutation is relatively uncommon. In antiretroviral-naïve patients, there is little baseline resistance to TDF. More than two of certain thymidine analog mutations (TAMS -- RT M41L, L210W, and T215Y/F) confer that resistance to TDF may be present. TDF does not select for TAMs. The RT M184V/I mutation is selected by both FTC and 3TC, though perhaps slightly less readily by the former, and leads to complete cross-resistance between the two. Interestingly, the M184V/I mutation can partially re-sensitize HIV that contains TAMs or the K65R mutation to TDF. Using FTC or 3TC with TDF may result in a somewhat higher barrier to drug resistance than seen with TDF alone, though several triple NRTI studies using TDF with FTC or 3TC have demonstrated that this theoretical benefit has limits.

A recent literature review indicated that resistance to FTC-TDF is relatively infrequent ([@b37]). Among the two Gilead clinical trials, a significant difference was seen in the proportion of patients receiving experiencing virologic rebound on therapy that developed the K65R mutation, with 22% (8 of 36) of patients in the 903 study and no patients in the 934 study developing the mutation ([@b43]). The reason for this discrepancy is unclear, though follow up in 903 was longer. The incidence of M184V/I in the TDF arm was 39% and 14%, respectively, but since the incidence of virologic rebound was small, these do not represent large numbers.

Toxicity and adverse reactions
==============================

TDF-FTC is generally well tolerated, with few side effects as noted above for the individual compounds. Lactic acidosis and hepatomegaly with steatosis, including fatal cases, have been reported with most other nucleosides but have not been reported to occur with TDF-FTC, to our knowledge ([@b17]).

TDF and FTC are principally eliminated via the kidneys. Like the known nephrotoxic NtRTIs cidofovir and adefovir, TDF is extracted from the blood plasma by the human renal organic anion transporters (hOAT1 and hOAT3), which has suggested the possibility of renal tubular toxicity ([@b57]). While the data concerning the clinical relevance on this are somewhat inconsistent ([@b31]; [@b16]; [@b43]; [@b15]), it appears that renal tubular toxicity, and occasionally Fanconi's syndrome (renal tubular injury with severe hypophosphatemia, phosphoturia, and glycosuria), serious hyperkalemia ([@b53]), or acute interstitial nephritis may develop with TDF or TDF-FTC use. The majority of these cases occurred in patients with underlying systemic vascular insult, low glomerular filtration rates (GFR)/chronic renal failure, or in patients taking nephrotoxic agents. Certain genetic haplotypes may be associated in some cases ([@b22]), though a number of cases have occurred in patients without identifiable risk factors. Because certain protease inhibitors, including lopinavir and atazanavir, increase the serum levels of TDF by as much as 25%, this could be a risk factor for nephrotoxicity ([@b25]; [@b18]), and extra caution is advised. The drug should be used only with great caution in patients with reduced GFR. All HIV infected patients, particularly those on TDF, should have baseline and yearly determination of GFR using either the Cockcroft-Gault or modification of diet in renal disease (MDRD) method, as well as regular assessments of serum blood urea nitrogen and creatinine. Consideration should be given to monitoring serum phosphate in those on TDF as well. Significant GFR or serum phosphate decline should prompt further evaluation and strong consideration for discontinuation of TDF ([@b46]; [@b38]; [@b52]; [@b1]; [@b23]; [@b17]). It is not well-elucidated if TDF-induced renal tubular toxicity routinely results in phosphaturia or glycosuria, so the absence of these cannot be relied upon to exclude a role for TDF in a patient's renal failure.

Subclinical renal phosphate wasting could possibly contribute to a decrease in bone mineral density that was reported in a study conducted among treatment-naïve patients who were treated with TDF in Gilead 903 ([@b8], [@b9]). A decrease in bone mineral density at the lumbar spine and hip, especially between weeks 24 and 48, was evident but was non-progressive through 288 weeks. Thus, monitoring of bone mineral density should be considered in patients with history of, or risk factors for, pathologic fractures. To the knowledge of the authors, no study has examined the benefit of calcium and vitamin D supplementation or bisphosponates in this setting.

Use of TDF-FTC has been associated with fewer overall adverse effects than D4T-3TC or ZDV-3TC. Compared with ZDV, TDF is associated with a lower frequency of anemia (4% vs 9%, respectively; p = 0.02) ([@b13]), and compared with D4T, TDF is associated with fewer lipid abnormalities.

Both TDF and abacavir containing regimens are associated with less severe side effects or improvements in lipoatrophy, a reduction in subcutaneous fat tissue, particularly in the face and extremities. This condition may result from mitochondrial toxicity induced in particular by the thymidine analog NRTIs, ZDV and D4T. In Gilead 934, limb fat, measured by whole-body DEXA at weeks zero and 96, was significantly greater in the TDF + FTC + efavirenz group versus the ZDV + 3TC + efavirenz group (7.7 vs 5.5 kg; p \< 0.001) ([@b43]). A similar lipoatrophy benefit with TDF was observed in an analysis restricted to African or African American study participants ([@b15]). An interesting twist to this story was suggested by AIDS Clinical Trial Group (ACTG) study 5142, which confirmed greater limb fat loss with D4T as compared with AZT, and ZDV as compared with TDF containing regimens; but in addition, NNRTI containing regimens were associated with greater fat loss than PI containing regimens, independent of which NRTi/NtRTI was used ([@b20]). The mechanism for an apparent lipoatrophy-potentiating effect of NNRTIs on NRTIs is not understood at this time, but this study should prompt further investigation.

Drug interactions
=================

It is assumed that drug interaction for TDF-FTC is the same when administered combined or dosed alone as TDF or FTC. Any medications that reduce renal function may increase concentration of FTC and TDF. No drug interactions with clinical consequences are known for FTC. As mentioned above, co-administration of TDF with certain protease inhibitors, including atazanavir, lopinavir/ritonavir, and darunavir (TMC-114)/ritonavir ([@b21]) results in increased plasma levels of TDF and, in the case of atazanavir and lopinavir/ritonavir, reduced protease inhibitor troughs. While no dose adjustment is recommended when TDF is used with these drugs ([@b3]; [@b10]), in cases where baseline protease resistance mutations have modestly raised the concentration of the drug required to inhibit the virus, this effect of TDF could be significant. Atazanvir should always be ritonavir boosted (atazanavir 300 mg should be boosted with ritonavir 100 mg) when used with TDF.

TDF should be used very cautiously with didanosine due to increased rates of adverse reactions including peripheral neuropathy and pancreatitis. This is likely a result of a drug interaction resulting in a 40%--50% increase in plasma didanosine levels ([@b44]) and/or intracellular drug interactions. In addition, use of TDF with didanosine has also been associated with paradoxical CD4 declines or less than robust CD4 increases in some, but not all studies ([@b2]; [@b24]; [@b56]). These results are reminiscent of those seen in studies combining didanosine with hydroxyurea. If co-administration of didanosine and TDF is necessary, didanosine dose should be adjusted and patients should be closely monitored for didanosine-related adverse reactions. The recommended didanosine dose for patients weighing \>60 kg in this setting is 250 mg; however, there is no adequate information for patients weighing below 60 kg ([@b17]).

Conclusion
==========

There is sufficient data to recommend the use of TDF-FTC in the treatment of HIV. It is recommended as a preferred and alternative treatment of choice in both treatment-naïve and experienced patients. In addition to its demonstrated efficacy, TDF-FTC also provides significant advantages in terms of few side effects, low long-term toxicity, once daily dosing, few drug interactions, useful anti-HBV activity, and a relatively high genetic barrier relative to other NRTIs/NtRTIs ([Table 4](#tbl4){ref-type="table"}). Caution must be exercised in patients with reduced renal function and when the drug is used with certain other antiretrovirals.

###### 

Advantages and disadvantages of TDF-FTC

                  TDF-FTC
  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Advantages      Potent antiretroviral activityNo food effectLonger intracellular half-life than 3TCOnce-daily regimenEffective against HBVWell toleratedAvoid or delay Thymidine Analog Mutations (TAMs)Low potential for mitochondrial toxicity
  Disadvantages   Rapid selection of 184V RT mutation in non-suppressive regimen with substantial loss of activityRapid selection of 184V RTRisk of Abacavir (ABC) and Didanosine (ddl) cross-resistance after failure (K65R) Tenofovir disoproxil fumarate (TDF) interaction to decrease levels of ATV (use ATV/r)In general, Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) may cause hepatotoxicity with elevated transaminases. Reported rates of grads 3--4 hepato toxicity are 8%--15%, and highest with NVP ([@b32]; [@b27]; [@b54])
